CytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease
VANCOUVER, Washington, May 17, 2017, CYDY, (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of ...
Home » Phase 2
VANCOUVER, Washington, May 17, 2017, CYDY, (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of ...
NXS - TSX.V Phase 2 Drilling Underway at Niangouela, Burkina Faso, West Africa Reports Higher Gold Assays from Phase 1 ...